- RecruitingPHASE3
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
This study investigates if a new drug, vicadrostat, combined with empagliflozin, can help adults with heart failure and a weakened heart pump. Participants will take study medications for up to 3.5 years, alongside their usual care.
For: Heart FailureUnited States · Argentina · Belgium - RecruitingPHASE3
A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)
This study for children aged 2-17 with kidney disease looks at a medicine called empagliflozin. We want to see if it helps their kidneys and how well their body handles it. Participants take the medicine or a dummy pill for 6 months, then everyone takes the medicine for a year.
For: Chronic Kidney DiseaseUnited States · Argentina · Australia - RecruitingPHASE3
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
This study looks at a new medicine, vicadrostat, for people with type 2 diabetes, high blood pressure, and heart disease. It aims to see if taking vicadrostat alongside empagliflozin can help reduce heart problems. Half the participants will get the study medicine, and half will get a dummy pill.
For: Diabetes Mellitus, Type 2 · Hypertension · Cardiovascular DiseasesUnited States · Argentina · Australia - Active not recruitingPHASE2
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease
This study looks at a new medicine, vicadrostat, combined with empagliflozin, for adults with chronic kidney disease. Participants will take pills daily for 3 months, with regular checks on their kidney health and general well-being. It aims to see if starting medicines at different times impacts results.
For: Chronic Kidney DiseaseUnited States · Argentina · Australia - RecruitingPHASE3
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
This study looks into a new treatment for adults with heart failure. It combines two medicines, vicadrostat and empagliflozin, to see if they can improve heart health in people with a specific type of heart failure. Participants take tablets daily and are closely monitored.
For: Heart FailureUnited States · Argentina · Australia - RecruitingPHASE3
Randomised Evaluation of COVID-19 Therapy
The RECOVERY trial looks at treatments for serious lung infections like pneumonia, including COVID-19. It helps doctors find the best ways to help hospitalised patients get better and reduce their risk of dying. Many treatments have been tested, and some have been found to be very helpful.
For: PneumoniaBelgium · Estonia · France - RecruitingPhase II
Repurposing empagliflozin for Duchenne muscular dystrophy-associated cardiomyopathy in children 6-18 years of age
This study looks at whether a medicine called empagliflozin can help children and young people (aged 6-18) with Duchenne muscular dystrophy (DMD) who also have heart problems. It aims to find the right dose and check if it's safe and helpful.
For: Duchenne muscular dystrophy (DMD) - associated cardiomyopathyUnited Kingdom · England - RecruitingPHASE1, PHASE2
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
This study looks at different treatment combinations for advanced breast cancer, including those that have spread or are hard to remove. Doctors want to see how well these new drug combinations work and if they are safe for patients.
For: Metastatic Breast CancerUnited States · Australia · France - RecruitingPHASE3
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
This study looks at a new medicine, BI 690517, combined with empagliflozin, for adults with chronic kidney disease. It aims to see if this combination can help slow down kidney disease progression and protect the heart, for people with and without type 2 diabetes.
For: Kidney Disease, ChronicUnited States · Argentina · Australia